AstraZeneca Phase 3 trial of its vaccine in US confirmed efficacy updated

AstraZeneca positive primary analysis of Phase 3 trial of its vaccine in the US

  • 76% vaccine efficacy against symptomatic COVID-19
  • 100% efficacy against severe and critical disease
  • 85% efficacy for those aged 65+

That 76% is down from 79% in a statement the firm issued only on Monday. 

Source

Leave a Reply

Your email address will not be published. Required fields are marked *